News

Our CEO, Dr.Nishino, will be speaking at the "International Open Innovation & Startup Symposium 2025," hosted by Institute of Science Tokyo, on Wednesday, July 23. We would be honored if you could attend and listen to his talk.(For details, click here)

Our website has been updated, and now includes information on each of our pipelines. We encourage you to visit and explore the new content.

AntiCancer Technologies Inc. has opened official social media accounts to strengthen information dissemination. We will continue to share company initiatives and announcements.
・Facebook ・ LinkedIn・ X (formerly Twitter)・Instagram

We have been selected for the startup support program "NCC Seed Acceleration Program (NCC SAP)" hosted by the National Cancer Center Japan's Center for Translational Research. (For details, click here)

We have published research results obtained through the development of cancer immunotherapy and molecular targeted drugs in multiple peer-reviewed academic journals. A list of papers published since 2011 is reported here.

AntiCancer Technologies Inc. was selected as the 11th support destination for "1stRound," Japan's largest academia-co-sponsored entrepreneurship support program by The University of Tokyo's Collaborative Creation Platform Development Co., Ltd. (UTokyo IPC) (article here)

The achievements of the Nakayama Laboratory will be broadcast on BS Tokyo "Ima kara Science" (from 10 PM on Wednesday, June 19) (Click here for photos, click here for preview)

AntiCancer Technologies Inc. (Chiyoda-ku, Tokyo) conducted a third-party allotment capital increase with multiple angel investors as underwriters.

An introduction to AntiCancer Technologies Inc. was featured in Nikkei Biotech's "Venture Exploration" (Click here for the article)

Website opened.

Certified as a Tokyo Medical and Dental University Startup

Filed basic patent for Pipeline 1.

CSO Nakayama had a discussion with Mr. Takafumi Horie (See link)

Company established.